Press Release Details

Cerus Corporation Announces New CFO and Promotions to Vice President for Commercialization

January, 20 1999

CONCORD, Calif., Jan. 20 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS) announced today that Robert Miller has joined the company as vice president of finance and chief financial officer.

The company also announced the promotions of David Cook, Ph.D. and Gary Wiesehahn, Ph.D. to vice presidents for commercialization. Jointly, they will be responsible for developing the company's pathogen inactivation systems for blood products intended for transfusion.

"These changes in our organization mark the significant progress we have made at Cerus," said Cerus president and chief executive officer Stephen Isaacs. "Bob comes to us with significant operational experience as well as several years on Wall Street. Gary and Dave have been involved in the development of our pathogen inactivation systems from the very early stages. They will now shift the focus of their responsibilities to our commercial strategy as our lead products for platelets and fresh frozen plasma move into later stage clinical trials. I expect all three to be working very closely with our corporate partner, Baxter Healthcare, to that end."

Bob Miller formerly served as CFO of several companies in the medical, high technology, retail and industrial products industries. Most recently, he held the position of chief financial officer and vice president of marketing for MedAcoustics, a private medical diagnostic imaging company. He also worked as an investment banker for Blyth Eastman Dillon, Inc. and Merrill Lynch and served as a Captain in the U.S. Marine Corps. Mr. Miller holds an MBA from Columbia University and a BA in Economics from Stanford University.

David Cook joined Cerus in 1993 and has served as the program director for the development of the red blood cell pathogen inactivation system. He holds a Ph.D. in chemistry from the University of California at Berkeley, a BS in chemistry from California State University at Long Beach and a BA in American Studies from Harvard University. Gary Wiesehahn joined Cerus in 1994 and has served as the program director for the development of the fresh frozen plasma pathogen inactivation system. He holds a Ph.D. in chemistry from the University of California at Berkeley and an AB in chemistry from Cornell University.

The company's pathogen inactivation systems for platelets and plasma are based on the proprietary light-activated compound, S-59. The platelet system is currently in a European Phase 3 clinical study and the company is developing a protocol for a Phase 3 study in the U.S. The FFP system has received clearance to proceed into a Phase 2b patient study. The company's pathogen inactivation system for red blood cells, based on its proprietary pH-activated anchor-linker-effector (ALE) compound, S-303, is in a Phase 1a clinical trial in healthy subjects.

Cerus Corporation is developing systems designed to enhance the safety of blood transfusions by inactivating pathogens in blood components (platelets, plasma and red blood cells used for transfusion) and by inactivating white blood cells, which are responsible for a variety of adverse transfusion reactions. The company's platform technologies, which prevent viral, bacterial and cellular replication, may have potential applications in the health care field beyond pathogen inactivation in blood components.

Cerus Corporation is collaborating with the Fenwal Division of Baxter Healthcare Corporation to develop, manufacture and market pathogen inactivation systems for blood components used for transfusion. Baxter, a global medical products and services company, focuses on critical therapies for life-threatening conditions. Baxter is a leader in technologies related to blood and the circulatory system. The Fenwal Division develops, manufactures and markets products and services for the collection, separation, storage and transfusion of blood and its components.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any trials, regulation by the FDA, the uncertainty of replication of animal data in humans, the uncertainty of market acceptance of any products, competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1997 Annual Report on Form 10-K.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600